m+Medelevator.RU
← Поиск публикаций
Nucleic acids research · 2026

PCNA-RECQL5-RPRD1B recruit repair components to stressed replication forks to promote survival of BRCA1-deficient cancer cells.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Tran Manh Tien, Williamson Elizabeth A, Jaiswal Aruna S, Arris Dominic, Nguyen Nhat, Carrillo Andrew, Olsen Shaun, Kong Kimi, Shaheen Montasser, Sadadeen Doraid, Zhou Daohong, Yuan Yaxia, Syed Shahrez, Kwon Youngho, Salunkhe Sameer, Sung Patrick, Hromas Robert

Аннотация

Given their defect in homologous recombination, BRCA1-deficient cancers use polymerase theta (POLQ) microhomology-mediated end joining (MMEJ) for repair of stressed replication forks. We found that BRCA1-deficient cells repress microRNA (miR) 4485-3p, and reconstituting expression of this miR resulted in the death of BRCA1-deficient cells. In our interrogation of the mechanism of this synthetic lethality, we discovered that miR-4485-3p suppresses expression of RPRD1B protein. Depletion of RPRD1B led to selective BRCA1-deficient cell death, decreased MMEJ, and decreased replication fork repair after replication stress. RPRD1B promotes the recruitment of the MMEJ components 53BP1, PARP1, and POLQ to the stressed replication fork. However, RPRD1B does not have a canonical DNA-binding domain, and our search for the mechanism of its recruitment to stressed replication forks discovered that this is mediated by RECQL5 and ubiquitinated (Ub) PCNA. Thus, our results unveil an essential signaling cascade at the stressed replication fork in BRCA1-deficient cancer cells, in which Ub PCNA recruits RECQL5, which recruits RPRD1B to mediate the assembly of the MMEJ repair apparatus. These data suggest that this repair scaffold may be targeted in the development of a novel synthetic therapy of BRCA1-deficient cancers.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты